Fierce Pharma Asia—Takeda’s lung cancer nod; 4th death in Astellas’ gene therapy trial; Everest’s mRNA playnews2021-09-17T09:12:19+00:00September 17th, 2021|Fierce Pharma|
Pfizer recalls all Chantix lots nationwide over concerns of cancer-causing impuritynews2021-09-16T20:18:29+00:00September 16th, 2021|Fierce Pharma|
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persistnews2021-09-16T18:05:35+00:00September 16th, 2021|Fierce Pharma|
Social media deliver pitfalls and positives for pharmas engaging cancer community, agency saysnews2021-09-16T17:27:54+00:00September 16th, 2021|Fierce Pharma|
ESMO: Merck details Keytruda’s ‘practice-changing’ cervical cancer survival winnews2021-09-16T15:57:04+00:00September 16th, 2021|Fierce Pharma|
ESMO: With Mirati hot on its tail, Amgen’s KRAS-targeting Lumakras combo heads into late-stage colorectal cancer testingnews2021-09-16T15:39:49+00:00September 16th, 2021|Fierce Pharma|
FDA greenlights batches of J&J COVID-19 vaccine from embattled Emergent site: reportnews2021-09-16T14:43:41+00:00September 16th, 2021|Fierce Pharma|
Not your grandma’s arthritis: Arthritis Foundation’s latest campaign focuses on younger demographicnews2021-09-16T13:50:39+00:00September 16th, 2021|Fierce Pharma|
ESMO: Merck’s Keytruda tames stage 2 melanoma, reducing cancer recurrence in postsurgery usenews2021-09-16T13:45:22+00:00September 16th, 2021|Fierce Pharma|
Merck, Codexis extend supply deal for key API in Januvia, Janumetnews2021-09-16T13:40:47+00:00September 16th, 2021|Fierce Pharma|
